Ibex Investors’s Galmed Pharmaceuticals GLMD Stock Holding History

Ibex Investors’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-607	Closed	-$1.59M	–	41
2021 Q4	$1.59M	Sell	607 -222	-27%	-$802K	0.53%	25
2021 Q3	$3.33M	Sell	829 -19	-2%	-$79.7K	0.7%	17
2021 Q2	$3.71M	Sell	848 -211	-20%	-$918K	1.38%	8
2021 Q1	$5.23M	Hold	1,059	–	–	1.8%	13
2020 Q4	$4.74M	Buy	1,059 +7	+0.7%	+$35K	1.89%	11
2020 Q3	$5.35M	Buy	1,052 +368	+54%	+$2.4M	2.82%	11
2020 Q2	$4.71M	Buy	684 +14	+2%	+$94.5K	2.24%	14
2020 Q1	$3.34M	Buy	670 +6	+0.9%	+$45.6K	3.36%	8
2019 Q4	$5.52M	Buy	664 +1	+0.2%	+$6.87K	0.1%	10
2019 Q3	$4.57M	Buy	663 +102	+18%	+$819K	0.29%	14
2019 Q2	$5.93M	Buy	561 +103	+22%	+$1.06M	0.48%	17
2019 Q1	$5.39M	Buy	458 +111	+32%	+$1.29M	0.48%	14
2018 Q4	$3.42M	Buy	347 +57	+20%	+$796K	0.56%	17
2018 Q3	$5.68M	Buy	290 +55	+23%	+$1.03M	3.15%	6
2018 Q2	$4.03M	Buy	235 +61	+35%	+$706K	2.29%	12
2018 Q1	$1.39M	Buy	174 +16	+10%	+$186K	1.15%	17
2017 Q4	$2.08M	Buy	+158	New	+$1.87M	1.21%	11

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BAM

Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

Ibex Investors's GLMD Position: Q1 2022 in Review

Ibex Investors sold out of Galmed Pharmaceuticals (GLMD) in Q1 2022, closing a stake of 607 shares — an estimated $1.59M sold.

Ibex Investors first reported a position in GLMD in Q4 2017 and held it in 17 quarters. The position peaked at $5.93M in Q2 2019. 20 funds tracked by Wall St. Rank hold GLMD as of Q1 2022.

Ibex Investors reported no remaining Galmed Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Ibex Investors sold 607 Galmed Pharmaceuticals shares in Q1 2022, an estimated $1.59M.
Ibex Investors first reported a position in Galmed Pharmaceuticals in Q4 2017 and held it in 17 quarters.
Ibex Investors's Galmed Pharmaceuticals position peaked at $5.93M in Q2 2019.
20 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2022.

Based on Ibex Investors's 13F filing for Q1 2022, filed 29 Apr 2022.